Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition